At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 253 enrolled
Drug / intervention
allopurinol +1 moredrug
Likely dose
allopurinol 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
In Brief
A Phase 2 clinical trial evaluating allopurinol and sugar pill for Heart Failure and Elevated Serum Uric Acid. Completed, enrolled 253 participants across 10 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Elevated Serum Uric Acid
CountriesCanada, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartMay 2010
Primary CompletionDec 2013
Study CompletionJun 2014
TodayJul 2026
First PostedOct 1, 2009
Enrollment StartMay 1, 2010
Primary CompletionDec 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 16.8 years ago
Interventions
allopurinoldrug
Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
sugar pilldrug
Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.